Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TAFASITAMAB-CXIX: 736 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
736
Total FAERS Reports
108 (14.7%)
Deaths Reported
117
Hospitalizations
736
As Primary/Secondary Suspect
19
Life-Threatening
2
Disabilities
Prescription
Status

FDA Application: 761163 ·

First Report: 20171101 · Latest Report: 20250809

What Are the Most Common TAFASITAMAB-CXIX Side Effects?

#1 Most Reported
Disease progression
218 reports (29.6%)
#2 Most Reported
Lymphoma
158 reports (21.5%)
#3 Most Reported
Off label use
126 reports (17.1%)

All TAFASITAMAB-CXIX Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Disease progression 218 29.6% 41 8
Lymphoma 158 21.5% 3 7
Off label use 126 17.1% 7 20
Death 53 7.2% 53 3
Drug ineffective 39 5.3% 19 5
Blood lactate dehydrogenase increased 34 4.6% 14 0
Diffuse large b-cell lymphoma 32 4.4% 13 4
Malignant neoplasm progression 30 4.1% 5 3
Neutropenia 30 4.1% 5 7
Polyneuropathy 29 3.9% 0 8
Covid-19 28 3.8% 9 17
Cytopenia 25 3.4% 0 1
Ill-defined disorder 21 2.9% 0 1
Product use issue 21 2.9% 2 1
Neoplasm progression 20 2.7% 7 0
Pneumonia 19 2.6% 2 16
Infection 17 2.3% 6 1
Pyrexia 17 2.3% 1 12
General physical health deterioration 15 2.0% 3 1
Pancytopenia 15 2.0% 1 6

Who Reports TAFASITAMAB-CXIX Side Effects? Age & Gender Data

Gender: 47.5% female, 52.5% male. Average age: 68.1 years. Most reports from: US. View detailed demographics →

Is TAFASITAMAB-CXIX Getting Safer? Reports by Year

YearReportsDeathsHosp.
2017 1 0 0
2018 6 0 0
2019 1 0 0
2020 21 3 4
2021 42 6 18
2022 83 17 25
2023 62 17 29
2024 12 2 1
2025 2 0 0

View full timeline →

What Is TAFASITAMAB-CXIX Used For?

IndicationReports
Diffuse large b-cell lymphoma 429
Product used for unknown indication 115
Follicular lymphoma 58
Diffuse large b-cell lymphoma refractory 31
Lymphoma transformation 23
Lymphoma 13
Marginal zone lymphoma 13
Diffuse large b-cell lymphoma recurrent 8
Non-hodgkin's lymphoma 7
B-cell lymphoma 5

TAFASITAMAB-CXIX vs Alternatives: Which Is Safer?

TAFASITAMAB-CXIX vs TAFINLAR TAFASITAMAB-CXIX vs TAFLUPROST TAFASITAMAB-CXIX vs TAGRAXOFUSP-ERZS TAFASITAMAB-CXIX vs TAHOR TAFASITAMAB-CXIX vs TALAZOPARIB TAFASITAMAB-CXIX vs TALC TAFASITAMAB-CXIX vs TALIGLUCERASE ALFA TAFASITAMAB-CXIX vs TALIMOGENE LAHERPAREPVEC TAFASITAMAB-CXIX vs TALQUETAMAB TAFASITAMAB-CXIX vs TALQUETAMAB-TGVS

Official FDA Label for TAFASITAMAB-CXIX

Official prescribing information from the FDA-approved drug label.